432 items to be re-evaluated for bioequivalence

Published: 2011-01-05 06:57:00

Updated: 2011-01-05 06:57:00

The Korea food and Drug Administration announced on January 3 that a total of 432 drugs (23 active pharmaceutical ingredients), including combination drugs, will be re-evaluated for bioequivalence.

By combined active substance, the bioequivalence re-assessment program will cover glibenclamide/metformin (60 products), amoxycillin/sulbactam (31 products), atenolol/chlorthalidone (25 products) ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.